Peter M. Castleman - 09 Jan 2026 Form 4 Insider Report for Caris Life Sciences, Inc.

Role
Director
Signature
/s/ J. Russel Denton, Attorney-in-Fact
Issuer symbol
CAI on Nasdaq
Transactions as of
09 Jan 2026
Net transactions value
+$46,500
Form type
4
Filing time
13 Jan 2026, 18:37:09 UTC
Previous filing
17 Jun 2025
Next filing
27 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
CASTLEMAN PETER M Director C/O CARIS LIFE SCIENCES, INC., 750 W. JOHN CARPENTER FREEWAY, SUITE 800, IRVING /s/ J. Russel Denton, Attorney-in-Fact 13 Jan 2026 0001239594

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CAI Common Stock Options Exercise $46,500 +2,500 +16% $18.60 18,629 09 Jan 2026 Direct
holding CAI Common Stock 100,000 09 Jan 2026 By Family Trust
holding CAI Common Stock 10,270,906 09 Jan 2026 By CLS-PF-SPE, LLC F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CAI Stock Option Options Exercise $0 -2,500 -100% $0.000000 0 09 Jan 2026 Common Stock 2,500 $18.60 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 CLS-PF-SPE Manager, LLC is the manager of CLS-PF-SPE, LLC. Mr. Castleman is a manager of CLS-PF-SPE Manager, LLC and in such capacity has voting and investment power with respect to the shares held by CLS-PF-SPE, LLC. The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein.
F2 The stock option is fully vested and exercisable. These securities were previously reported on the Reporting Person's Form 3.